Drug intelligence / Profile preview

AT673

Development stage: Phase 2
Lead developer: Antag Therapeutics
Modality: Peptides
Administration: Subcutaneous

Overview

AT673 is a first-in-class, once-weekly injectable peptide antagonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor, developed by Antag Therapeutics. While many metabolic therapies utilize GIP receptor agonism, AT673 is based on the premise that blocking GIP signaling can inhibit fat deposition and promote weight loss. The drug is currently in Phase 2 development, where it is being studied in combination with the GLP-1 receptor agonist semaglutide to evaluate its potential for providing additive efficacy in weight reduction and glycemic control for patients with type 2 diabetes and obesity.

Targets

GIPR (Gastric inhibitory polypeptide receptor)

Beyond the preview

Go deeper on AT673.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT673.

Explore the full profile